Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Show more...
FAQ
Intra-Cellular Therapies 今天的股價是多少?▼
I2TC34.SA 目前價格為 R$125.76 BRL,過去 24 小時上漲了 +0%。在圖表上更密切關注 Intra-Cellular Therapies 股價表現。
Intra-Cellular Therapies 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Intra-Cellular Therapies 的股票以代號 I2TC34.SA 進行交易。
Intra-Cellular Therapies 去年的營收是多少?▼
Intra-Cellular Therapies 去年的營收為 3.82BBRL。
Intra-Cellular Therapies 去年的淨利是多少?▼
I2TC34.SA 去年的淨收益為 -414.95MBRL。
Intra-Cellular Therapies 會發放股息嗎?▼
是的,I2TC34.SA 的股息每 zh-tw 發放一次。每股最新股息為 122.58 BRL。截至今日,股息殖利率(FWD)% 為 0%。
Intra-Cellular Therapies 有多少名員工?▼
截至 April 03, 2026,公司共有 860 名員工。
Intra-Cellular Therapies 位於哪個產業?▼
Intra-Cellular Therapies從事於Health Care產業。
Intra-Cellular Therapies 何時完成拆股?▼
Intra-Cellular Therapies 最近沒有進行任何拆股。
Intra-Cellular Therapies 的總部在哪裡?▼
Intra-Cellular Therapies 的總部位於 US 的 Bedminster。